World APS Day: Shining a Light on a Silent but Life-Threatening Autoimmune Disorder
The APS Foundation of America has shared an important update on their official X page in recognition of World APS Day. The post emphasizes the urgent need to raise awareness about Antiphospholipid Syndrome (APS)—an incurable, life-threatening autoimmune disorder that increases the risk of dangerous blood clots.
“Today is World APS Day, the global awareness campaign to raise awareness of Antiphospholipid Syndrome and its impact on our lives.
APS is an incurable, life-threatening autoimmune condition that causes the blood to clot.”
What is APS?
APS occurs when the immune system mistakenly produces antibodies that target phospholipids—critical components of cell membranes—leading to an increased risk of:
- Deep vein thrombosis (DVT)
- Pulmonary embolism
- Stroke
- Recurrent miscarriage
- Catastrophic multiorgan thrombosis in severe cases
Despite its profound clinical impact, APS remains underdiagnosed and misunderstood.
Hemostasis Today proudly joins the global movement to raise awareness, promote early diagnosis, and support ongoing research into this devastating condition. As we commemorate World APS Day, we stand with patients, families, and advocates in calling for increased education, improved testing, and more targeted therapies.
Let today be a reminder: Clots can kill, but knowledge can save lives.
Follow us on Hemostasis Today for expert insights, clinical updates, and patient stories throughout APS Awareness Month.
-
Aug 2, 2025, 18:28Filippo Crea Shares Some AI-Insights on Recurrent STEMI
-
Aug 2, 2025, 18:05MSK Cancer Center CME: Expert Insights on Benign Hematology, Hemostasis and Thrombosis
-
Aug 2, 2025, 17:56“Impressive Work!” – Flora Peyvandi on Laurence Zitvogel’s Recent Article
-
Aug 2, 2025, 17:44Understanding ESR: Dr. William Aird Breaks Down the Factors Behind Sedimentation Rate Changes
-
Aug 2, 2025, 17:34Oral Anticoagulation in VTE: Apixaban Safer and More Effective than Rivaroxaban or Warfarin
-
Aug 2, 2025, 04:31Acute VTE in Women: Continue Contraception, Select the Right Anticoagulant
-
Aug 1, 2025, 13:11Isabelle Mahé Shares an Insight from APICAT Study: Use of Apixaban in Cancer Associated Thrombosis
-
Jul 31, 2025, 16:12Samin Mohsenian Shares the Final Open Access Version: Ob/Gyn Complications and Congenital Fibrinogen Disorders
-
Jul 31, 2025, 15:45Tzu-Fei Wang: To Anticoagulate or Not To Anticoagulate—That Is The Question
-
Jul 31, 2025, 15:12Wolfgang Miesbach: Protecting Liver Health in Bleeding Disorders
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 31, 2025, 15:37Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab
-
Jul 28, 2025, 12:53Zambia’s Hemophilia Prophylaxis Success
-
Jul 26, 2025, 16:14Cesar Garrido: Forging Strong Partnerships on WHA78 ''Global Health Equity'' Event
-
Jul 23, 2025, 15:34Don't Miss the Hemophilia B Virtual Event on July 29 – Sign Up Now!
-
Jul 23, 2025, 11:05Haemnet Gives Voice to Parents Facing the Challenges of Childhood Bleeding Disorders